NCT04691011 (IRM-SLA) is a NA clinical trial of Muscular MRI in Amyotrophic Lateral Sclerosis, sponsored by Assistance Publique Hopitaux De Marseille.

Who is sponsoring NCT04691011?

NCT04691011 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT04691011?

Interventions in NCT04691011: Muscular MRI, Electrophysiological exam, Brain MRI, Spinal cord MRI.

What condition does NCT04691011 study?

NCT04691011 studies Amyotrophic Lateral Sclerosis.

Is NCT04691011 still recruiting?

NCT04691011 is currently completed. Last updated 30 January 2026.

Last reviewed 2026-01-30 · How we verify

NCT04691011: IRM-SLA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Completed NA Last updated 30 January 2026

What this trial tests

NA trial testing Muscular MRI in Amyotrophic Lateral Sclerosis in 22 participants. Completed in 4 June 2025.

Timeline

16 June 2021

Primary endpoint
4 June 2025

4 June 2025

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	22
Start date	16 June 2021
Primary completion	4 June 2025
Estimated completion	4 June 2025
Sites	1 location across France

Drugs / interventions tested

Muscular MRI
Electrophysiological exam
Brain MRI — full drug profile →
Spinal cord MRI

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

TDP-43-proteinopathy at the crossroads of tauopathy: on copathology and current and prospective biomarkers.
Nasir AR, Delpirou Nouh C. · · 2025 · PMID 41229731 · DOI 10.3389/fncel.2025.1671419

Verify or expand the search:

Other trials of Muscular MRI

Trials testing the same drug.

NCT06354790 — Natural History Study of Children With LAMA2-related Dystrophies · recruiting

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04691011 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 30 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04691011.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing